MGMT and glioblastoma: Prognostic value—Currently, poor overall prognostication of tumors is based on independent risk factors such as histological grade and clinical data; in addition, molecular subtypes play an important role in response to treatment and overall survival of brain tumors [12,109]: for instance, MGMT mutation in GBM can improve treatment response [110], and IDH mutation is an important prognostic factor for patients with improved survival rates compared to IDH wildtype glioblastoma [111,112].